Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > It’s over.

<< Previous

Bullboard Posts

Next >>

Post by Rarbar99on Aug 17, 2021 1:32pm

507 Views

Post# 33717622

It’s over.

Today's report was the final nail in the coffin.

Ever after the stock dropped 65% overnight, only 1 out of 40 insiders bought the dip, and he only bought around 10K shares at a price of $1.03 which is laughable considering he is the CEO..

In today's report, they made sure to bring up the fact that they're beginning to focus on their new projects/upcoming drugs. It's seems like they're trying to prolong this fiasco as long as possible, but they know otenproxesual is going to be a failed drug. Sucks but this is the reality.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario